Antiviral drug allergy.
Milpied-Homsi B, Moran EM, Phillips EJ.
Immunol Allergy Clin North Am · research-article; review; journal article · DOI 10.1016/j.iac.2014.04.011 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för rilpivirine. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
40 träffarRilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.
Anta L, Llibre JM, Poveda E, Blanco JL, Alvarez M, Pérez-Elías MJ, Aguilera A, Caballero E, Soriano V, de Mendoza C, Resistance Platform of the Spanish AIDS Research Network.
AIDS · research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1097/qad.0b013e3283584500Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection.
Lyseng-Williamson KA, Scott LJ.
Clin Drug Investig · journal article · DOI 10.1007/bf03261925Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.
Vingerhoets J, Rimsky L, Van Eygen V, Nijs S, Vanveggel S, Boven K, Picchio G.
Antivir Ther · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.3851/imp2358Biochemical mechanism of HIV-1 resistance to rilpivirine.
Singh K, Marchand B, Rai DK, Sharma B, Michailidis E, Ryan EM, Matzek KB, Leslie MD, Hagedorn AN, Li Z, Norden PR, Hachiya A, Parniak MA, Xu HT, Wainberg MA, Sarafianos SG.
J Biol Chem · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1074/jbc.m112.398180Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review.
Schafer JJ, Short WR.
Antivir Ther · research support, non-u.s. gov't; systematic review; journal article · DOI 10.3851/imp2254Liquid chromatography-tandem mass spectrometric assay for the non-nucleoside reverse transcriptase inhibitor rilpivirine in human plasma.
Burugula L, Pilli NR, Makula A, Lodagala DS, Kandhagatla R.
Biomed Chromatogr · journal article · DOI 10.1002/bmc.2765Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.
Balamane M, Varghese V, Melikian GL, Fessel WJ, Katzenstein DA, Shafer RW.
Antimicrob Agents Chemother · brief-report; journal article; research support, n.i.h., extramural · DOI 10.1128/aac.00648-12Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.
Cohen CJ, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, Wu H, Johnson MA, Saag M, Supparatpinyo K, Crauwels H, Lefebvre E, Rimsky LT, Vanveggel S, Williams P, Boven K, ECHO Study Group, THRIVE Study Group.
J Acquir Immune Defic Syndr · clinical trial, phase iii; comparative study; randomized controlled trial; journal article · DOI 10.1097/qai.0b013e31824d006eRilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection.
Fernández-Montero JV, Vispo E, Anta L, de Mendoza C, Soriano V.
Expert Opin Pharmacother · research support, non-u.s. gov't; journal article · DOI 10.1517/14656566.2012.667802Rilpivirine: a second-generation nonnucleoside reverse transcriptase inhibitor.
James C, Preininger L, Sweet M.
Am J Health Syst Pharm · journal article · DOI 10.2146/ajhp110395New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir.
Patel N, Miller CD.
HIV AIDS (Auckl) · review-article; journal article · DOI 10.2147/hiv.s25149Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era.
De Clercq E.
Biochem Pharmacol · review; journal article · DOI 10.1016/j.bcp.2012.03.024Effects of rilpivirine on human adipocyte differentiation, gene expression, and release of adipokines and cytokines.
Díaz-Delfín J, Domingo P, Mateo MG, Gutierrez Mdel M, Domingo JC, Giralt M, Villarroya F.
Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.00104-12Rilpivirine.
Sanford M.
Drugs · review; journal article · DOI 10.2165/11208590-000000000-00000Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Sun LQ, Qin B, Huang L, Qian K, Chen CH, Lee KH, Xie L.
Bioorg Med Chem Lett · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.bmcl.2012.02.055The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness.
Kulkarni R, Babaoglu K, Lansdon EB, Rimsky L, Van Eygen V, Picchio G, Svarovskaia E, Miller MD, White KL.
J Acquir Immune Defic Syndr · journal article · DOI 10.1097/qai.0b013e31823aca74Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.
Rimsky L, Vingerhoets J, Van Eygen V, Eron J, Clotet B, Hoogstoel A, Boven K, Picchio G.
J Acquir Immune Defic Syndr · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1097/qai.0b013e31823df4daBoceprevir, telaprevir, and rilpivirine hydrochloride.
Hussar DA, Snell CW.
J Am Pharm Assoc (2003) · journal article · DOI 10.1331/japha.2012.12506Prevalence of TMC278 (rilpivirine) associated mutations in the Frankfurt Resistance Database.
Reinheimer C, Doerr HW, Stürmer M.
J Clin Virol · journal article · DOI 10.1016/j.jcv.2011.12.012Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects.
Crauwels H, Vingerhoets J, Ryan R, Witek J, Anderson D.
Antivir Ther · research support, non-u.s. gov't; clinical trial, phase i; journal article; case reports · DOI 10.3851/imp1959Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial.
Wilkin A, Pozniak AL, Morales-Ramirez J, Lupo SH, Santoscoy M, Grinsztejn B, Ruxrungtham K, Rimsky LT, Vanveggel S, Boven K, TMC278-C204 Study Group.
AIDS Res Hum Retroviruses · clinical trial, phase iii; clinical trial, phase ii; multicenter study; randomized controlled trial; journal article · DOI 10.1089/aid.2011.0050Rilpivirine and complera: new first-line treatment options.
O'Neal R.
BETA · newspaper article; journal articleRilpivirine (Edurant)--a new drug for HIV infection.
Författaruppgift saknas
Med Lett Drugs Ther · journal articleRilpivirine: a step forward in tailored HIV treatment.
Schrijvers R, Desimmie BA, Debyser Z.
Lancet · comment; journal article · DOI 10.1016/s0140-6736(11)60992-6Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, Wu H, Zorrilla C, Crauwels H, Rimsky LT, Vanveggel S, Boven K, THRIVE study group.
Lancet · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s0140-6736(11)60983-5Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, Supparatpinyo K, Walmsley S, Crauwels H, Rimsky LT, Vanveggel S, Boven K, ECHO study group.
Lancet · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s0140-6736(11)60936-7Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings.
Ford N, Lee J, Andrieux-Meyer I, Calmy A.
HIV AIDS (Auckl) · review-article; journal article · DOI 10.2147/hiv.s14559Clinical Trial Report: TMC278 (Rilpivirine) Versus Efavirenz as Initial Therapy in Treatment-Naïve, HIV-1-Infected Patients.
Macarthur RD.
Curr Infect Dis Rep · journal article · DOI 10.1007/s11908-010-0148-6Rilpivirine: a new addition to the anti-HIV-1 armamentarium.
Miller CD, Crain J, Tran B, Patel N.
Drugs Today (Barc) · review; journal article · DOI 10.1358/dot.2011.47.1.1583188